Scancell Holdings plc
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Scancell Holdings plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies and vaccines for cancer treatment. The company develops products using its four proprietary technology platforms: Moditope and ImmunoBody for vaccines, and GlyMab and AvidiMab for antibodies. Its product pipeline includes vaccine candidates Modi-1 and Modi-2, targeting citrullinated and homocitrullinated cancer antigens respectively, and ImmunoBody vaccines SCIB1 and iSCIB1+, which are in advanced clinical trials, particularly for melanoma treatment. Scancell’s antibody portfolio includes candidates such as SC134, designed as T-cell redirecting antibodies for cancers including small cell lung cancer. Founded in 1996 and headquartered in Oxford, UK, Scancell operates primarily in the UK and aims to address unmet clinical needs in oncology with off-the-shelf cancer immunotherapies that stimulate durable systemic immune responses. Recent developments include the initiation of a new arm (Cohort 4) in the ongoing Phase 2 SCOPE study, evaluating intradermal administration and accelerated dosing regimens for its iSCIB1+ vaccine in advanced unresectable melanoma patients. The company reported positive Phase 2 clinical data demonstrating a progression-free rate exceeding historical standard-of-care benchmarks. It has advanced towards registration by submitting regulatory documentation to FDA and other agencies for randomized studies planned for 2026. Scancell also secured £12.1 million in funding and forged a strategic partnership with the Cancer Vaccine Launchpad to fast-track melanoma patient access. Organizationally, it has strengthened its leadership team with key pharmaceutical industry appointments to accelerate commercial capabilities. The company continues to develop its GlyMab platform via the establishment of Glymab Therapeutics Ltd to enhance antibody product development execution and commercial potential. These initiatives position Scancell for near-term clinical milestones and potential commercialization within the oncology immunotherapy market.
Company News
Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial
Scancell Holdings secures $25m financing as it advances melanoma trial
Cancer vaccine breakthrough at Moderna raises hopes for Scancell's melanoma programme
Marvell shares jump as Google warrant deepens AI chip partnership
Scancell secures UK clearance for late-stage melanoma trial
Ford and GM upgraded by Jefferies on improving outlooks, stronger cash generation
Chip stocks slide as China advances domestic lithography, memory production
Scancell sees high demand in retail share offer, seals £15.7m from UK investors
SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612
American Airlines shares fall as fuel costs weigh on third-quarter outlook despite earnings beat
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Scancell to join Nasdaq through Neuphoria merger and $89 million funding package
Scancell to join Nasdaq through Neuphoria merger and $89 million funding package
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Scancell confirms advanced talks over reverse merger with Neuphoria
Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up
Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up
Scancell wins FDA fast-track status for melanoma immunotherapy
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
US banks set to deliver solid first quarter results amid macroeconomic uncertainty